GHK-Cu targets pathways relevant to both male and female pattern hair loss: Wnt/beta-catenin activation, TGF-beta1 suppression, VEGF upregulation, and DPC survival
doi:10.1016/j.tips.2013.01.001
It appears in peptide catalogues because of the research context it sits in, not because it shares any chemistry with the peptides around it, and nearly every instinct developed handling lyophilised peptides is the wrong instinct here
Importantly, ~25% of patients with MASLD do not have obesity, but they show even higher risks than patients with obesity of developing severe metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis and hepatocellular carcinoma 4 because they miss timely screening owing to their normal body weights
Where do you inject GHK-Cu
Nature 348 , 728730 (1990)